Increased frequency of metabolic syndrome and its individual metabolic abnormalities in japanese patients with primary gout

Journal of Clinical Rheumatology

Volumn 16, Issue 3, 2010, Pages 109-112

  Inokuchi, Taku ^a   Tsutsumi, Zenta ^a   Takahashi, Sumio ^a   Ka, Tsuneyoshi ^a   Moriwaki, Yuji ^a   Yamamoto, Tetsuya ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Abdominal adiposity; Adipocytokines; Uric acid

Indexed keywords

ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOREACTIVITY; INSULIN RESISTANCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; WAIST CIRCUMFERENCE;

ADIPOKINES; ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; GOUT; HUMANS; JAPAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE;

EID: 77951057656     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181c6802e     Document Type: Article

References (38)

1. Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066-3072.
2. Kumada M, Kihara S, Sumitsuji S, et al; Osaka CAD Study Group. Coronary artery disease: association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85-89.
3. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes. 2002;51:2325-2328.
4. Ishizaka N, Ishizaka Y, Toda E, et al. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005;25:1-7.
5. Numata T, Miyatake N, Wada J, et al. Comparison of serum uric acid levels between Japanese with and without metabolic syndrome. Diabetes Res Clin Pract. 2008;80:e1-e5.
6. Sui X, Church TS, Meriwether RA, et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57:845-852.
7. Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57:109-115.
8. Vazquez-Mellado J, Garcia CG, Vazquez SG, et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol. 2004;10:105-109.
9. Rho YH, Choi SJ, Lee Ji JD, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005;20:1029-1033.
10. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977; 20:895-900.
11. An examination committee for criterion of metabolic syndrome: definition and criteria of metabolic syndrome -in Japanese. Nippon Naika Gakkai Zasshi. 2005;94:794-809.
12. Takahashi S, Moriwaki Y, Tsutsumi Z, et al. Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout. Metabolism. 2001;50:393-398.
13. Japanese Society of Gout and Nucleic Acid Metabolism. Guidelines for the Management of Hyperuricemia and Gout. Tokyo, Japan: Japanese Society of Gout and Nucleic Acid Metabolism; 2002.
14. Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology: from West to the rest. Diabetes Care. 1992;15:232-252.
15. Onat A, Uyael H, Hergenc G, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens. 2006;19: 1055-1062.
16. Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res. 2006;37:883-889.
17. Choi HK, Ford ES. Prevalence of metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442-447.
18. Nakagawa T, Kang DH, Feig D, et al. Unearthing uric acid: An ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int. 2006;26:1722-1725.
19. Takahashi S, Yamamoto T, Tsutsumi Z, et al. Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. Metabolism. 1997;46:162-165.
20. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29:1350-1355.
21. Ter Maaten JC, Voorburg A, Heine RJ, et al. Renal handling of urate and sodium during acute physiological hyperinsulinemia in healthy subjects. Clin Sci. 1997;92:51-58.
22. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006; 290:F625-F631. (Pubitemid 43724964)
23. Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294:F710-F718.
24. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739-1742.
25. Yigner O, Ozcelik F, Inanc T, et al. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol. 2008;97:334-340.
26. Roy D, Perreault M, Marette A. Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol. 1998;274:E692-E699.
27. Cheung KJ, Tzameli I, Pissios P, et al. Xanthine oxidoreductase is a regulator of adipogenesis and PPAR g activity. Cell Metab. 2007;5:115-128.
28. Matsuura F, Yamashita S, Nakamura T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998;47:929-933.
29. Yü T, Talbott JH. Changing trends of mortality in gout. Semin Arthritis Rheum. 1980;10:1-9.
30. Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41:237-242.
31. Trock D. Tired, achy, and overweight, the inflammatory nature of obesity. J Clin Rheumatol. 2009;15:50.
32. Tamba S, Nishizawa H, Funahashi T, et al. Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Intern Med. 2008;47:1175-1180.
33. Bo S, Gambino R, Durazzo M, et al. Association between serum uric acid and adipokines, markers of inflammation, and endothelial dysfunction. J Endocrinol Invest. 2008;31:499-504.
34. Fruehwald-Schultes B, Peters A, Kern W, et al. Serum leptin is associated with serum uric acid concentration in humans. Metabolism. 1999;48:677-680.
35. Matsubara M, Chiba H, Maruoka S, et al. Elevated serum leptin concentrations in women with hyperuricemia. J Atheroscler Thromb. 2002;9:28-34.
36. Bedir A, Topbas M, Tanyeri F, et al. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J. 2003;44:527-536.
37. Lindeman JH, Piil H, Toet K, et al. Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int J Obes (Lond). 2007;31:1671-1679.
38. Zonana-Nacach A, Santana-Sahagun E, Jimenez-Balderas FJ, et al. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol. 2008;14:74-77.